Sartorius Stedim with clear analyst picture, shares tracked against parent stock

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 18:49.

Sartorius Stedim Biotech (FR0013154002) sits in the shadow of its German parent Sartorius, whose preference shares trade in the DAXsector Pharma & Healthcare on Xetra under the ticker SRT3. Analyst updates on the parent, including a recent Goldman Sachs stance, help shape sentiment for the French bioprocessing group.

What analysts say on Sartorius

For the German-listed Sartorius preference shares, Goldman Sachs recently reiterated a Neutral view, according to a research summary cited by MarketScreener on June 23, 2026. This stance underscores a cautious but not pessimistic positioning toward the broader Sartorius group, which includes Sartorius Stedim Biotech as a core subsidiary.

Additional coverage compiled by BCC Research highlights Sartorius as a global player in bioprocess technology with around €4.0 billion in revenue in 2025 and roughly 14,000 employees worldwide, emphasizing its diversified geographic exposure across Europe, the Americas and Asia-Pacific. These scale indicators provide an anchor for valuation debates around both the German and French listings.

Parent stock performance as a reference

On the German market, Sartorius preference shares recently traded around €230 on platforms such as OnVista, with intraday gains of more than 5 percent reported for June 25, 2026 on the Stuttgart venue. The shares are classified in the specialized machinery and pharma & healthcare segment, making them a reference point for investors assessing Sartorius Stedim’s positioning in the broader life-science tools sector.

Finanzen100 likewise lists the Sartorius preference shares under ticker SRT3 in the DAXsector Pharma & Healthcare Performance Index, confirming the stock’s role as a benchmark within the European healthcare equipment universe. For many international investors, this German reference is the primary liquidity pool that indirectly informs views on Sartorius Stedim Biotech.

The business behind Sartorius Stedim

Sartorius Stedim Biotech focuses on bioprocess solutions for the development and manufacture of biopharmaceuticals, with single-use technologies for cell culture and purification at its core, as detailed on its investor relations pages. The group’s portfolio ranges from bioreactors and filtration systems to analytics tools for quality control in biomanufacturing.

Where the shares trade today

The Sartorius Stedim Biotech shares (FR0013154002) are listed in Paris; a precise live price and timestamp for today’s session were not reliably available across the usual data portals at the time of writing, so only the listing venue can be stated without quoting a current level.

This text is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instruments. Accuracy of data is based on the cited sources at the time of editing and may change without notice.